<DOC>
	<DOCNO>NCT03079687</DOCNO>
	<brief_summary>This open-label , single-arm , international , multicenter Multiple Patient Expanded Access Program ( MPEAP ) . The program design provide treatment access olaparib tablet patient platinum-sensitive relapsed high-grade epithelial ovarian , fallopian tube primary peritoneal cancer without treatment option eligible olaparib clinical trial .</brief_summary>
	<brief_title>Expanded Access Program Olaparib Tablets Maintenance Therapy Patients With Ovarian , Fallopian Tube Primary Peritoneal Cancer .</brief_title>
	<detailed_description>The Multiple Patient Expanded Access Program design provide treatment access olaparib tablet patient platinum-sensitive relapsed high-grade epithelial ovarian , fallopian tube primary peritoneal cancer response ( complete response partial response ) follow platinum-based chemotherapy . The dose olaparib tablet 300 mg ( two 150 mg tablet ) take twice daily , equivalent total daily dose 600 mg . The 100 mg tablet available dose reduction . Treatment may continue disease progression , unacceptable toxicity withdrawal patient consent . The program collect observational data .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Poly ( ADP-ribose ) Polymerase Inhibitors</mesh_term>
	<criteria>Inclusion criterion For inclusion program patient must fulfill follow criterion : Provision inform consent prior program specific procedure Female patient â‰¥ 18 year age platinumsensitive relapse high grade epithelial ovarian , primary peritoneal fallopian tube cancer Patient response ( complete response partial response ) follow platinumbased chemotherapy . Patients must normal organ bone marrow function measure within 28 day prior administration program treatment . Postmenopausal evidence nonchildbearing status woman childbearing potential . Exclusion criterion : Patients enter program follow exclusion criterion fulfil : Patients know hypersensitivity olaparib excipients product . Concomitant use know strong CYP3A inhibitor moderate CYP3A inhibitor . Concomitant use know strong moderate CYP3A inducer . The required washout period prior start olaparib 5 week enzalutamide phenobarbital 3 week agent . Patient moderate severe hepatic impairment . Breast feeding woman .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Ovarian cancer</keyword>
	<keyword>gynaecological cancer</keyword>
	<keyword>platinum-sensitive disease</keyword>
	<keyword>platinum-sensitive relapse</keyword>
	<keyword>Olaparib</keyword>
	<keyword>Ovarian Neoplasms</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Ovarian Disease</keyword>
	<keyword>fallopean tube cancer</keyword>
	<keyword>primary peritoneal cancer</keyword>
	<keyword>epithelial ovarian cancer</keyword>
	<keyword>PARP inhibitor</keyword>
	<keyword>Poly ( ADP-ribose ) polymerase inhibitor .</keyword>
</DOC>